Show results for
Refine by
Tyrosine Kinase Inhibitor Equipment & Supplies
71 equipment items found
Manufactured by:Taiho Oncology, Inc. based inPrinceton, NEW JERSEY (USA)
Tyrosine Kinase Inhibitor of EGFR exon 20 insertion mutations. Non-Small Cell Lung Cancer (Phase 1/2) PHASE ...
Manufactured by:MedChemExpress LLC (MCE) based inMonmouth Junction, NEW JERSEY (USA)
Tyrosine kinase inhibitor is a potent tyrosine kinase ...
Manufactured by:ALL Chemistry Inc. based inMarlton, NEW JERSEY (USA)
Falnidamol (BIBX 1382) is an orally active, selective EGFR tyrosine kinase inhibitor with an IC50 of 3 nM. Falnidamol is 1000 times more selective for ErbB2 (IC50=3.4 μM) and a range of other related tyrosine kinases (IC50 >>10 μM). Falnidamol is a pyrimidine-pyrimidine compound with anti-cancer ...
Manufactured by:Saladax Biomedical, Inc. based inBethlehem, PENNSYLVANIA (USA)
Targeted therapies are revolutionizing oncology. Patients with chronic myeloid leukemia treated with the tyrosine kinase inhibitors (TKI) now have life expectancies approaching that of the general population. Imatinib (Gleevec®, Gilvec®) the first TKI approved has substantial efficacy in chronic myeloid leukemia (CML) and gastrointestinal ...
by:F. Hoffmann-La Roche Ltd. based inBasel, SWITZERLAND
Alecensa is a highly selective, central nervous system-active, oral medicine used for the treatment of people with non-small cell lung cancer (NSCLC) whose tumours are identified as anaplastic lymphoma kinase (ALK)-positive. Alecensa is a tyrosine kinase inhibitor that targets ALK fusion proteins, preventing signalling within ...
Manufactured by:MedChemExpress LLC (MCE) based inMonmouth Junction, NEW JERSEY (USA)
Imatinib Mesylate (STI571 Mesylate) is a tyrosine kinases inhibitor that inhibits c-Kit, Bcr-Abl, and PDGFR (IC50=100 nM) tyrosine ...
Manufactured by:MedChemExpress LLC (MCE) based inMonmouth Junction, NEW JERSEY (USA)
Orantinib (SU6668; TSU-68) is a multi-targeted receptor tyrosine kinase inhibitor with Kis of 2.1 μM, 8 nM and 1.2 μM for Flt-1, PDGFRβ and FGFR1, ...
Manufactured by:MedChemExpress LLC (MCE) based inMonmouth Junction, NEW JERSEY (USA)
Lenvatinib mesylate (E7080 mesylate), an oral, multi-targeted tyrosine kinase inhibitor that inhibits VEGFR1-3, FGFR1-4, PDGFR, KIT, and RET, shows potent antitumor ...
Manufactured by:MedChemExpress LLC (MCE) based inMonmouth Junction, NEW JERSEY (USA)
Lenvatinib (E7080) is an oral, multi-targeted tyrosine kinase inhibitor that inhibits VEGFR1-3, FGFR1-4, PDGFR, KIT, and RET, shows potent antitumor ...
Manufactured by:MedChemExpress LLC (MCE) based inMonmouth Junction, NEW JERSEY (USA)
Axitinib-13C,d3 is a 13C-labeled and deuterium labeled Axitinib. Axitinib is a multi-targeted tyrosine kinase inhibitor with IC50s of 0.1, 0.2, 0.1-0.3, 1.6 nM for VEGFR1, VEGFR2, VEGFR3 and PDGFRβ, ...
Manufactured by:MedChemExpress LLC (MCE) based inMonmouth Junction, NEW JERSEY (USA)
Cediranib (AZD2171) is a highly potent, orally available VEGFR tyrosine kinase inhibitor with IC50s of <1, <3, 5, 5, 36, 2 nM for Flt1, KDR, Flt4, PDGFRα, PDGFRβ, c-Kit, ...
Manufactured by:BridgeBio Pharma, Inc. based inPalo Alto, CALIFORNIA (USA)
Infigratinib is an orally administered, ATP-competitive, FGFR1-3 tyrosine kinase inhibitor in development for the treatment of FGFR-driven cancers. Multiple Phase 3 clinical trials are currently enrolling; please explore www.clinicaltrials.gov for more information. TRUSELTIQ™ (infigratinib) obtained accelerated approval by FDA, was ...
Manufactured by:MedChemExpress LLC (MCE) based inMonmouth Junction, NEW JERSEY (USA)
Lenvatinib-d4 is the deuterium labeled Lenvatinib. Lenvatinib (E7080) is an oral, multi-targeted tyrosine kinase inhibitor that inhibits VEGFR1-3, FGFR1-4, PDGFR, KIT, and RET, shows potent antitumor ...
Manufactured by:BridgeBio Pharma, Inc. based inPalo Alto, CALIFORNIA (USA)
Infigratinib (BGJ398), is an orally administered, ATP-competitive, FGFR1-3 tyrosine kinase inhibitor in development for the treatment of FGFR-driven conditions, including achondroplasia, a bone growth disorder in children. Overactivating FGFR3 mutations drive downstream MAPK and STAT1 signaling that aberrates growth plate development, thereby ...
Manufactured by:MedChemExpress LLC (MCE) based inMonmouth Junction, NEW JERSEY (USA)
Sunitinib (SU 11248) is a multi-targeted receptor tyrosine kinase inhibitor with IC50s of 80 nM and 2 nM for VEGFR2 and PDGFRβ, respectively[1]. Sunitinib, an ATP-competitive inhibitor, effectively inhibits autophosphorylation of Ire1α by inhibiting autophosphorylation and consequent RNase ...
Manufactured by:MedChemExpress LLC (MCE) based inMonmouth Junction, NEW JERSEY (USA)
Sunitinib Malate (SU 11248 Malate) is a multi-targeted receptor tyrosine kinase inhibitor with IC50s of 80 nM and 2 nM for VEGFR2 and PDGFRβ, respectively[1]. Sunitinib Malate, an ATP-competitive inhibitor, effectively inhibits autophosphorylation of Ire1α by inhibiting autophosphorylation and consequent RNase ...
Manufactured by:MedChemExpress LLC (MCE) based inMonmouth Junction, NEW JERSEY (USA)
NVP-ADW742 (ADW742) is an orally active, selective IGF-1R tyrosine kinase inhibitor with an IC50 of 0.17 μM. NVP-ADW742 inhibits insulin receptor (InsR) with an IC50 of 2.8 μM. NVP-ADW742 induces pleiotropic antiproliferative/proapoptotic biologic sequelae in tumor ...
Manufactured by:MedChemExpress LLC (MCE) based inMonmouth Junction, NEW JERSEY (USA)
CP-724714 is a potent, selective and orally active ErbB2 (HER2) tyrosine kinase inhibitor, with an IC50 of 10 nM. CP-724714 displays a marked selectivity against EGFR kinase (IC50=6400 nM). CP-724714 potently inhibits ErbB2 receptor autophosphorylation in intact cells. Antitumor ...
Manufactured by:MedChemExpress LLC (MCE) based inMonmouth Junction, NEW JERSEY (USA)
Ceritinib (LDK378) is a selective, orally bioavailable, and ATP-competitive ALK tyrosine kinase inhibitor with an IC50 of 200 pM. Ceritinib (LDK378) also inhibits IGF-1R, InsR, and STK22D with IC50 values of 8, 7, and 23 nM, respectively. Ceritinib (LDK378) shows great antitumor ...
Manufactured by:MedChemExpress LLC (MCE) based inMonmouth Junction, NEW JERSEY (USA)
Amuvatinib (MP470) is an orally bioavailable multi-targeted tyrosine kinase inhibitor with potent activity against mutant c-Kit, PDGFRα, Flt3, c-Met and c-Ret. Amuvatinib (MP470) is also a DNA repair suppressor through suppression of DNA repair protein RAD51, thereby disrupting DNA damage repair[1][2][3]. ...